Article Text

Download PDFPDF
Case series
Treatment of cerebral vasospasm with self-expandable retrievable stents: proof of concept
  1. Pervinder Bhogal1,
  2. Yince Loh2,3,
  3. Patrick Brouwer1,
  4. Tommy Andersson1,
  5. Michael Söderman1
  1. 1The Karolinska University Hospital, Stockholm, Sweden
  2. 2Uniformed Services University, University of California, Los Angeles, California, USA
  3. 3Swedish Neuroscience Institute, Seattle, Washington, USA
  1. Correspondence to Dr P Bhogal, Flat 26 Imperial Hall, 104–122 City Road, London EC1V 2NR, UK; bhogalweb{at}aol.com

Abstract

Objective To report our preliminary experience with the use of stent retrievers to cause vasodilation in patients with delayed cerebral vasospasm secondary to subarachnoid hemorrhage.

Methods Four patients from two different high volume neurointerventional centers developed cerebral vasospasm following subarachnoid hemorrhage. In addition to standard techniques for the treatment of cerebral vasospasm, we used commercially available stent retrievers (Solitaire and Capture stent retrievers) to treat the vasospastic segment including M2, M1, A2, and A1. We evaluated the safety of this technique, degree of vasodilation, and longevity of the effect.

Results Stent retrievers can be used to safely achieve cerebral vasodilation in the setting of delayed cerebral vasospasm. The effect is long-lasting (>24 hours) and, in our initial experience, carries a low morbidity. We have not experienced any complications using this technique although we have noted that the radial force was not sufficient to cause vasodilation in some instances. The vasospasm did not return in the vessel segments treated with stent angioplasty in any of these cases. In two of our cases stent angioplasty resulted in the reversal of focal neurological symptoms.

Conclusions Stent retrievers can provide long-lasting cerebral vasodilation in patients with delayed cerebral vasospasm.

  • Aneurysm
  • Stroke
  • Stent
  • Subarachnoid

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors PeB designed the study. PeB, YL, and MS provided cases. PeB produced the article. PaB and TA edited and reviewed the paper. MS is guarantor.

  • Competing interests PeB is a consultant for Blockade. YL is a consultant for Blockade, Medtronic and Microvention. PaB is a consultant for Stryker and Codman. TA is a consultant for Stryker, Covidien, Neuravi, and Rapid Medical. MS is a consultant for Blockade and Neuravi.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement We have several other unpublished cases that will be part of a larger series to be produced at a later stage. These are not available to other colleagues at the current time.